Pharvaris N.V. Ordinary Shares(PHVS)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $16.00 – $33.33
- YTD
- +16.27%
- IV Rank (30D)
- 64.21
- Straddle Price
- $8.05
- P/C Vol Ratio
- 10.00
- Market Cap
- $2.3B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.03% (VRP-adj) |
| WACC | 10.01% |
| Volatility Risk Premium | +71.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $29.59 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $30.29 |
| Bollinger Width / SMA20 | 44.1% (drives anchor stability) |
| Net Debt | $0.0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 23.4× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 15.1× · 7 peers |
| Peer P/B | n/a | 0% | median 7.8× · 8 peers |
| Peer P/S | n/a | 0% | median 5.1× · 7 peers |
| Market Anchor (SMA50) | $29.59 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
- Exchange
- XNAS
- Market Cap
- $2.3B
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studie…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +1.07% | 5 |
| Feb | +0.67% | 6 |
| Mar | +0.79% | 6 |
| Apr | +7.46% | 6 |
| May | -7.23% | 6 |
| Jun | +14.79% | 6 |
| Jul | +0.57% | 5 |
| Aug | -1.46% | 5 |
| Sep | -2.30% | 5 |
| Oct | -4.00% | 5 |
| Nov | -11.90% | 5 |
| Dec | +96.27% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall assessment: NEUTRAL with confidence level (6/10)
Key drivers:
- Technical signals are mixed, with a bullish MACD and RSI in neutral territory
- Recent news headlines have been mostly positive, but not significantly impacting the stock price
- Risk metrics indicate moderate volatility, following market trends
Primary risks:
- Earnings data is unavailable, making it difficult to assess earnings expectations
- Options market sentiment is bearish, with a put/call volume ratio of 10.00
Investment thesis: PHVS has a neutral technical stance and mixed news sentiment. The lack of earnings data hinders risk assessment, but the options market suggests caution. With moderate volatility, this stock may be suitable for traders seeking to capitalize on price movements.
Recent news sentiment impact: Positive news headlines have not significantly impacted the stock price, likely due to the bullish MACD signal being somewhat muted by the neutral RSI reading.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): NEUTRAL, Medium-term (1-3 months): BULLISH, Long-term (3-12 months): BEARISH
Support/Resistance Levels:
- Lower: $28.26 (Bollinger Band Lower)
- Middle: $30.29 (SMA 50)
- Upper: $32.31 (Bollinger Band Upper)
Momentum Signals:
- RSI interpretation: Neutral (51.98)
- MACD signal: Bullish (0.53 / Signal: 0.10 / Histogram: 0.43)
- Bollinger Bands position: Squeeze
Volume Analysis: Volume trends are mixed, with a volume rate of change indicating a decline in trading activity.
News & Sentiment Analysis
Recent Headlines Summary: PHVS has experienced mostly positive news headlines, focusing on product developments and corporate events.
Sentiment Assessment: Aggregate news sentiment is NEUTRAL (positive 2/5, neutral 3/5).
Catalyst Identification: No significant catalysts are imminent, but upcoming earnings data could impact the stock price.
Market Narrative: The mixed technical signals and lack of significant news catalysts suggest a neutral market narrative for PHVS.
Risk & Volatility Assessment
Beta Interpretation: Beta is 0.92 (vs SPY), indicating moderate risk relative to the broader market.
Volatility Regime: Current volatility levels are above average, but not extreme.
Options Market Signals: IV rank: 64.2% (Medium), put/call volume ratio: 10.00 (Bearish).
Downside Protection: Support levels are in place at $28.26 and $30.29, providing some downside protection.
Market Context & Positioning
Sector Performance: PHVS is slightly outperforming its sector peers, suggesting a relative strength position.
Institutional Activity: No significant institutional activity has been observed recently.
Correlation Analysis: The stock's correlation with the broader market (R-squared) is 0.18, indicating limited dependence on market trends.
Relative Valuation: PHVS appears to be trading within its historical range, suggesting no significant valuation discrepancies.
Key Levels & Action Items
Critical Price Levels:
- Lower: $28.26 (Bollinger Band Lower)
- Middle: $30.29 (SMA 50)
- Upper: $32.31 (Bollinger Band Upper)
Breakout/Breakdown Levels: No specific levels have been identified, but the stock may be poised to break out or breakdown from its current trading range.
Time-Sensitive Catalysts: Earnings data is expected soon, which could significantly impact the stock price.
Risk Management: Consider using stop-loss levels at $28.26 and $30.29 for downside protection, with a position sizing consideration of 1-2% of the overall portfolio.
- IV Rank (30D)
- 64.21
- IV Rank (7D)
- 100
- Avg IV
- 115.0%
- Straddle (30D)
- $8.05
- Straddle (7D)
- $3.80
- P/C Volume
- 10.00
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.92
- Correlation (SPY)
- 17.8%
- R²
- 0.03
- Ann. Volatility
- 63.7%
- SPY Volatility
- 12.3%
Moderate volatility - stock generally follows market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC Custodian | $1.28M | 46.45% | 2026-03-31 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.18M | 42.96% | 2026-03-31 |
| 3 | SIMPLEX TRADING, LLC Custodian | $290.98K | 10.59% | 2026-03-31 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | Anna Nijdam | Principal Accounting Officer | Sell (S) | −2,670 | $30.87 | -$82.4K | EDGAR |
| 2026-05-26 | David W. Nassif | CFO / CLO | Sell (S) | −10,000 | $30.31 | -$303.1K | EDGAR |
| 2026-05-26 | Viviane Monges | Director | Sell (S) | −9,667 | $30.29 | -$292.9K | EDGAR |
| 2026-05-26 | Anna Nijdam | Principal Accounting Officer | Mixed | — | $25.35 | -$78.5K | EDGAR |
| 2026-05-22 | Elisabeth Bjork | Director | Mixed | — | $18.68 | -$212.7K | EDGAR |
| 2026-05-22 | Berndt Modig | Chief Executive Officer | — | — | — | EDGAR | |
| 2026-05-20 | Berndt Modig | Chief Executive Officer | Sell (S) | −2,292 | $29.22 | -$67.0K | EDGAR |
| 2026-05-19 | Wim Souverijns | Chief Commercial Officer | Sell (S) | −10,000 | $29.92 | -$299.2K | EDGAR |
| 2026-05-19 | Stefan Andreas Abele | Chief Technical Ops Officer | Sell (S) | −8,748 | $29.82 | -$260.9K | EDGAR |
| 2026-05-19 | Robert Glassman | Director | Mixed | −4,667 | $27.21 | -$179.3K | EDGAR |
| 2026-05-13 | Peng Lu | Chief Medical Officer | Tax (F) | −226 | $30.02 | -$6.8K | EDGAR |
| 2026-05-05 | Peng Lu | Chief Medical Officer | Mixed | — | $16.38 | -$390.7K | EDGAR |
| 2026-05-01 | Johannes Gerardus Christiaan Petrus Schikan | Director | Sell (S) | −32,900 | $30.29 | -$996.5K | EDGAR |
| 2026-05-01 | Anne Lesage | Chief Early Development | Mixed | −22,900 | $22.04 | -$1.30M | EDGAR |
| 2026-05-01 | Peng Lu | Chief Medical Officer | Mixed | — | $16.40 | -$517.3K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Berndt Modig | Chief Executive Officer | 1,087,500 | $33.41M | -$779.8K | 4 | 2026-05-22 |
| 2 | Johannes Gerardus Christiaan Petrus Schikan | Director | 384,237 | $11.80M | -$1.21M | 2 | 2026-05-01 |
| 3 | Anne Lesage | Chief Early Development | 213,319 | $6.55M | -$1.90M | 2 | 2026-05-01 |
| 4 | David W. Nassif | CFO / CLO | 120,300 | $3.70M | -$303.1K | 1 | 2026-05-26 |
| 5 | Peng Lu | Chief Medical Officer | 65,974 | $2.03M | -$1.21M | 5 | 2026-05-13 |
| 6 | Anna Nijdam | Principal Accounting Officer | 46,275 | $1.42M | -$307.5K | 5 | 2026-06-08 |
| 7 | Wim Souverijns | Chief Commercial Officer | 45,111 | $1.39M | -$299.2K | 1 | 2026-05-19 |
| 8 | Stefan Andreas Abele | Chief Technical Ops Officer | 35,194 | $1.08M | -$260.9K | 1 | 2026-05-19 |
| 9 | Elisabeth Bjork | Director | 15,167 | $465.9K | -$293.2K | 1 | 2026-05-22 |
| 10 | Robert Glassman | Director | 15,167 | $465.9K | -$298.2K | 1 | 2026-05-19 |
| 11 | Viviane Monges | Director | 5,500 | $169.0K | -$292.9K | 1 | 2026-05-26 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.